ZLZai Lab ZLAB · NASDAQ
$24.03 +9.03% (+$1.99)
- Market cap
- $2.46B
- Enterprise value
- $2.11B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 5.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -29.3%
- Gross margin
- 56.5%
- Net margin
- -41.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.83
- Free float
- 93.4%
About the company
Zai Lab Limited is a Chinese biotechnology company specializing in the development and commercialization of innovative drugs focused on the treatment of oncology and autoimmune diseases. The company concentrates on developing products in the fields of immunotherapy, targeted therapy, and other advanced treatment methods. Zai Lab collaborates with leading global pharmaceutical and biotechnology companies to bring the latest treatment options to the Chinese market and the broader Asia region, ensuring that patients have access to new therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Ying Du
Employees
1,784
Headquarters
Shanghai
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number